Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742986 | 0.97 | LMNA (0.59) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL8588233 | 0.97 | CYP2C19 (0.59) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL2763827 | 0.94 | LMNA (0.60) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL1744048 | 0.93 | LMNA (0.55) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL19261520 | 0.93 | LMNA (0.51) | LMNACYP2C19HIF1A | |
| SCHEMBL8587003 | 0.91 | CYP2C19 (0.65) | LMNACYP2C19HIF1AEGFRSRC | |
| Ioforminol SCHEMBL374830 | 0.91 | LMNA (0.65) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL19261519 | 0.90 | LMNA (0.54) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL16883242 | 0.90 | LMNA (0.49) | LMNACYP2C19HIF1A | |
| SCHEMBL2533624 | 0.89 | LMNA (0.42) | LMNACYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738596-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2017-08-22 | — | — | US | claimed |
| US-20150191422-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2015-07-09 | — | — | US | claimed |
| US-8920780-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2014-12-30 | — | — | US | claimed |
| EP-2178568-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2014-07-02 | — | — | EP | claimed |
| US-20110256068-A1 | CONTRAST MEDIA COMPOSITIONS | GE HEALTHCARE AS (NO) | 2011-10-20 | — | — | US | claimed |
| US-20100322868-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-23 | — | — | US | claimed |
| US-9738596-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2017-08-22 | — | — | US | disclosed |
| US-9738596-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2017-08-22 | — | — | US | disclosed |
| US-9738596-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2017-08-22 | — | — | US | disclosed |
| US-20150191422-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2015-07-09 | — | — | US | disclosed |
| US-20150191422-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2015-07-09 | — | — | US | disclosed |
| US-20150191422-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2015-07-09 | — | — | US | disclosed |
| US-8920780-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2014-12-30 | — | — | US | disclosed |
| US-20100322868-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-23 | — | — | US | disclosed |
| US-20100322868-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-23 | — | — | US | disclosed |
| WO-2010079201-A1 | CONTRAST MEDIA COMPOSITIONS | GE HEALTHCARE AS (NO) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079201-A1 | CONTRAST MEDIA COMPOSITIONS | GE HEALTHCARE AS (NO) | 2010-07-15 | — | — | WO | disclosed |
| EP-2178568-A2 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009008734-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009008734-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191422-A1 | CONTRAST AGENTS | SSTR3, INSR, INSRR | LMNA 1656/4885CYP2C19 3523/4885HIF1A 1391/4885 |
| US-20110256068-A1 | CONTRAST MEDIA COMPOSITIONS | FPR1, FPR3, TPO | LMNA 2641/4885CYP2C19 4295/4885HIF1A 1948/4885 |
| US-20100322868-A1 | CONTRAST AGENTS | SSTR3, INSR, INSRR | LMNA 1656/4885CYP2C19 3523/4885HIF1A 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.